

UK NEQAS for N-Methyl-D-Aspartate Receptor Antibodies (NMDAR)- Pilot

Accreditation Status:	<i>currently not accredited to ISO 17043</i>								
Date Scheme started:	2023								
Clinical Applicability:	Autoimmune encephalitis with no known common infectious cause								
Analytes:	NMDAR (SER/062)								
Units for Reporting:	Qualitative: Positive / Negative								
Samples Distributed:	Liquid format. Normal and pathological human serum								
Number of Distributions per year:	6								
Number of Samples per Distribution:	2								
Frequency of Distributions:	Every two months as outlined in the Distribution Schedule								
Schedule of Analysis:	Data entry is via the web for the submission of results. Data analysis is commenced 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics								
Data Analysis:	Qualitative responses are assessed by MI scoring in relation to the designated response								
Performance Scoring:	MI scoring								
Criteria of Performance:	<p>Laboratory performance is classified in terms of OMIS over a running analytical window of 6 distributions (12 months)</p> <p>The categories of performance are:</p> <table><thead><tr><th></th><th><u>Total MIS</u></th></tr></thead><tbody><tr><td>Good</td><td>zero</td></tr><tr><td>Adequate</td><td>1 - 2</td></tr><tr><td>Poor</td><td>>2</td></tr></tbody></table>		<u>Total MIS</u>	Good	zero	Adequate	1 - 2	Poor	>2
	<u>Total MIS</u>								
Good	zero								
Adequate	1 - 2								
Poor	>2								
Persistent Poor Performance:	Defined as being in the Poor Performance category for two or more successive Distributions.								